Poor Pregnant Women with Herpes Don’t Get Meds, and Someone Notices

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


GlaxoSmithKline, in testing their herpes med, Valtrex, may have put women in harm’s way. This according to Public Citizen, which, in the Dec 1 issue of Obstetrics and Gynecology accuses the pharma giant of withholding important medication from poor and minority women.

In a recent clinical trial 168 pregnant women were given a placebo rather than an alternative herpes drug, while the other 170 were given medication. This, despite the fact that research has shown that the drug and its generic, acyclovir, reduces risks associated with herpes and pregnancy (the virus can be fatal for infants who contract the disease at birth).

The study, which took place earlier this year and was funded by GlaxoSmithKline, enrolled more than 300 black and Hispanic pregnant women at Parkland Hospital in Dallas. The hospital serves a largely indigent population. Public Citizen’s Dr. Peter Lurie is outraged:

“What I don’t understand is how you can do a research study and conclude that a drug is effective and then stare a bunch of pregnant women in the face and withhold the very drug you’ve just recommended.”

A doctor involved in the study, Dr. George Wendel, would not comment specifically on allegations that poor women were taken advantage of, instead saying that the study was designed and conducted “according to good research practices” and was approved by the hospital’s ethics review board.

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate